Continuing Education Activity

Agranulocytosis is a condition in which the absolute neutrophil count (ANC) is less than 100 neutrophils per microlitre of the blood. Agranulocytosis may be acquired or inherited. It is a serious condition and can be life-threatening. Prompt diagnosis and treatment are needed to avoid mortality due to septicemia. This activity describes the etiology, evaluation, and management of the agranulocytosis and highlights the role of the interprofessional team in evaluating and improving care for patients with this condition.

Objectives:

• Describe the etiology of agranulocytosis.
• Identify the appropriate evaluation for agranulocytosis.
• Outline the management options available for agranulocytosis.
• Summarize the importance of collaboration and coordination among the interprofessional team to improve outcomes for those affected with agranulocytosis.

Introduction

Neutrophils are the most abundant white blood cell in blood and play a critical role in providing innate immunity against various offending agents. Agranulocytosis, also known as agranulosis or granulopenia, is an acute condition involving severe and dangerous neutropenia. Agranulocytosis is a condition in which the absolute neutrophil count (ANC) is less than 100 neutrophils per microlitre of blood. People with this condition are at a very high risk of severe infection. Broadly, it can be due to hereditary disease due to genetic mutation or acquired disease. Agranulocytosis can have various presentations, including fever, chills, sore throat, etc. It can be a life-threatening condition that requires prompt diagnosis and treatment.

Etiology

Agranulocytosis can be broadly classified into two distinct categories, inherited and acquired. The hereditary disease is due to genetic mutations in the gene coding for neutrophils elastase or ELA2. The most commonly seen mutations are intronic substitutions that inactivate a splice site in intron 4. Acquired diseases may be due to various medications,[1] chemicals, autoimmune conditions, and infections.

The following are the medications commonly involved with agranulocytosis:

• Cancer chemotherapies
• Analgesic and anti-inflammatory (gold, naproxen, and penicillamine)
• Anti-thyroid (carbimazole, propylthiouracil)[2][3]
• Anti-arrhythmics (quinidine, procainamide)
• Anti-hypertensives (captopril, enalapril, nifedipine)
• Anti-depressants/psychotropics (clozapine, amitriptyline, dosulepin, mianserin)
• Anti-malarials (pyrimethamine, dapsone, sulfadoxine, chloroquine)
• Anticonvulsants (phenytoin, sodium valproate, carbamazepine)[4]
• Antibiotics (sulphonamides, penicillin, cephalosporins)[5]
• Miscellaneous (cimetidine, ranitidine, chloropropamide, zidovudine)[6]

Infections that can cause agranulocytosis include:

• Bacterial (typhoid fever, shigella enteritis, brucellosis, tularemia, tuberculosis)
• Rickettsial (rickettsialpox, human granulocytic anaplasmosis, Rocky Mountain spotted fever)
• Parasitic (kala-azar, malaria)
• Viral (human immune deficiency, Epstein-Barr virus, cytomegalovirus, hepatitis viruses, human herpesvirus 6)

Autoimmune conditions such as lupus, rheumatoid arthritis, and bone marrow diseases like myelodysplastic and leukemias are also associated with agranulocytosis.

Epidemiology

Agranulocytosis is a rare condition and occurs in all age groups, with a reported incidence ranging from 6 to 8 cases per million population per year.[7] About 70% of the cases are found to be involved with medication usage. It also occurs more frequently in women than in men, either because of increased medication usage in females or due to increased incidence of autoimmune diseases in females. Agranulocytosis has no racial predilection.

Pathophysiology

Two main mechanisms responsible for agranulocytosis include inadequate or ineffective granulopoiesis and accelerated removal or destruction of neutrophils. Inadequate or ineffective granulopoiesis is due to generalized marrow failure. It also occurs in aplastic anemia, varieties of leukemias, myelodysplastic syndromes. Accelerated removal or destruction of neutrophils occurs due to immune-mediated injury to neutrophils or is idiopathic.

Histopathology

Marrow hypercellularity is seen when it results from excessive destruction of the mature neutrophils or ineffective granulopoiesis. In contrast, drugs that suppress granulocytopoiesis are associated with a marked decrease in mature granulocytic precursors in the marrow.[8]

History and Physical

A history of a new medication used or a change in medication, recent exposure to chemical or physical agents, or recent viral or bacterial infection is usually associated with agranulocytosis. A history of autoimmune disease or a strong family history of recurrent infection usually beginning from early childhood may be present. The initial symptoms are often malaise, fever, and chills, or infections, which usually present in the form of ulcers, necrotizing lesions of the gingiva, the floor of the mouth, buccal mucosa, pharynx, or other sites within the oral cavity.[9] Pharyngitis, with difficulty in swallowing and multiple skin abscesses, could be another presentation of the disease. As the onset of agranulocytosis can be abrupt, sepsis can be the presentation. On examination, a fever usually more than 40 degrees Celcius, tachycardia, tachypnea, and hypotension are usually present.

Evaluation

The diagnosis of agranulocytosis requires a high degree of suspicion based on signs and symptoms, medication use, recent exposure to chemical agents, and infections. A complete blood count (CBC) with the differential count is used in the initial workup. An absolute neutrophil count (ANC) of less than 100 neutrophils per microlitre of blood is necessary to diagnose the condition. The peripheral blood smear should assess neutrophil morphology. A Wright-stained peripheral smear will show a marked decrease and absence of neutrophils. Erythrocyte sedimentation rate (ESR), C reactive protein (CRP), coagulation studies (prothrombin time, partial thromboplastin time, D-dimer), lactate dehydrogenase (LDH), antinuclear antibody (ANA), rheumatoid factor (RF), liver function tests (LFT), renal function tests (RFT), and urine analysis can be used in patients with a relevant history. If the patient is febrile, cultures of the blood, urine, sputum and other suspected sites of infection should be taken. No imaging technique is used to diagnose agranulocytosis, but a chest X-ray (CXR) can be used for the initial workup. Further, bone marrow aspiration and biopsy can be used after an initial abnormal blood smear.

Treatment / Management

Agranulocytosis is a serious condition, and prompt treatment for it should be initiated. Once agranulocytosis is documented, any suspected offending medications or agents should be removed regardless of whether the patient is symptomatic or not. If it is due to drugs or offending agents, it usually resolves after one to three weeks after the offending agent is stopped. Meanwhile, general care like oral hygiene to prevent infection of the mucosa and teeth, control of oral and gingival lesion pain with anesthetic gel, and gargles are helpful. Stool softeners can be used in case of constipation. Skin infection and abrasion should be treated promptly.

Hematopoietic growth factors are used to accelerate the production, maturation, migration, and cytotoxicity of the neutrophils.[10] Filgrastim, a granulocyte colony-stimulating factor (G-CSF),[11] sargramostim, a granulocyte-macrophage colony-stimulating factor, pegfilgrastim (a long-acting filgrastim) are the agents used to treat agranulocytosis.

In case of infection, start specific antibiotic therapy with third-generation cephalosporins or equivalent. Cefepime,[12] carbapenems,[13] (e.g., meropenem, imipenem-cilastatin), or piperacillin-tazobactam can be used. In suspected cases of resistant bacteria, vancomycin or linezolid can be used in methicillin-resistant Staphylococcus aureus (MRSA). Linezolid or daptomycin can be used in cases of vancomycin-resistant enterococcus. Carbapenems can be used in the case of extended-spectrum beta-lactamase (ESBL) producing gram-negative bacteria. If the patient’s fever does not respond within 4-5 days or if the fever recurs with the administration of broad-spectrum antibiotics after an initial afebrile interval, consider adding empiric antifungal coverage with amphotericin B (preferably lipid formulation), a broad-spectrum azole (e.g., voriconazole), or an echinocandin (e.g., caspofungin).

Differential Diagnosis

Agranulocytosis should be differentiated from other conditions that cause bone marrow failure and leukemias. The following are the differential diagnosis of agranulocytosis:

• Aplastic anemia: Aplastic anemia is a condition of bone marrow failure characterized by features of pancytopenia. It includes signs and symptoms of anemia (pallor, fatigue, dizziness, murmur), petechial rashes, gingival bleeding, infections, and ulcerations.
• Acute myeloid leukemia (AML): Patients with AML present with signs and symptoms of bone marrow failure and organ infiltration. Bone marrow failure results in signs and symptoms of pancytopenia like pallor, fatigue, gingival bleeding, rashes, and infections.
• Acute lymphoblastic leukemia (ALL): ALL is a malignant disease of the bone marrow presenting with pancytopenia. It is the most common type of cancer and leukemia in children characterized by fever, pallor, fatigue, dizziness, bleeding, blood clots, lymphadenopathy, infections (pneumonia, and urinary tract infection).
• Human immune deficiency virus (HIV): Patients with HIV can present in any stage of the illness with flu-like illness, fever, malaise, rash, oral ulceration, and severe infections. A detailed history can help differentiate it from agranulocytosis.
• Epstein-Barr virus (EBV) infectious mononucleosis: EBV infectious mononucleosis is an infectious disease caused by EBV (human herpes virus-4). It presents with fatigue, malaise, sore throat, pharyngitis, and fever.
• Bacterial sepsis: Sepsis is a life-threatening condition characterized by fever (temperature more than 38 degrees Celcius, or less than 36 degrees Celcius) with or without chills, hypotension, tachypnea, respiratory infections, altered mental status, gastro-intestinal or genito-urinary infections.

Prognosis

A number of factors are associated with adverse prognosis in patients with agranulocytosis. These include:

• Age more than 65 years
• Absolute neutrophil count at the time of diagnosis less than 100/microlitre
• Development of severe intercurrent infection (e.g., septicemia, septic shock)
• Pre-existing comorbidities (e.g., renal, cardiac, respiratory, and systemic inflammatory diseases)

Complications

The main complication of agranulocytosis is infection. The duration and severity of agranulocytosis directly correlate with the incidence of infection. When the ANC remains lower than 100 cells per microlitre of blood for longer than 3-4 weeks, the incidence of infection approaches 100%.

Sepsis is another major complication of agranulocytosis. Sepsis is a clinical syndrome due to the dysregulated bodily response to infection. As the number of mature granulocytes is severely decreased in agranulocytosis, the body is no longer able to fight the offending agents leading to sepsis, bacteremia, and septic shock. Septic shock is a type of distributive or vasodilatory shock that leads to circulatory and metabolic abnormalities and is associated with a higher rate of mortality.

Deterrence and Patient Education

Patients starting a new drug or a change in medication that has the propensity of causing agranulocytosis should be informed about the potential adverse effect of the medicine. They should be educated about the importance of frequent CBC testing in the initial period of drug use. With the drop of ANC below the cut-off value, the offending agent must be identified and stopped irrespective of the clinical signs and symptoms of agranulocytosis. Patients are also required to avoid contact with people having respiratory tract infections, avoid going to crowded places, and asked to take proper precautions like a face mask and hand sanitizer whenever exposed to a crowded environment.

Enhancing Healthcare Team Outcomes

Agranulocytosis is a rare condition that may be asymptomatic or present with nonspecific symptoms and requires the efforts of an interprofessional team. In those patients taking new drugs or a change in their medications or undergoing cancer chemotherapy, providers should consider the possibility of agranulocytosis, especially when the patient has a fever or any clinical signs and symptoms of infection. The management involves interprofessional care that includes a hospitalist, intensivist, and pharmacist.

The patient monitoring is usually done by the nurses who should be aware of the condition and its presentation. The pharmacist should ensure that the patient is on the appropriate antibiotics in cases associated with sepsis. Also, the pharmacist must ensure that the patient has stopped using the offending agent. Close communication between the interprofessional team is vital to improving patient outcomes.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Andrès E, Federici L, Weitten T, Vogel T, Alt M. Recognition and management of drug-induced blood cytopenias: the example of drug-induced acute neutropenia and agranulocytosis. Expert Opin Drug Saf. 2008 Jul;7(4):481-9. [PubMed: 18613811]

2.

Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management. Drugs R D. 2017 Mar;17(1):91-96. [PMC free article: PMC5318340] [PubMed: 28105610]

3.

Andrès E, Weitten T, Mourot-Cottet R, Keller O, Zulfiqar AA, Serraj K, Vogel T, Tebacher M. [Antithyroid agents related agranulocytosis: Literature review]. Rev Med Interne. 2016 Aug;37(8):544-50. [PubMed: 27241077]

4.

Wiciński M, Węclewicz MM. Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring. Curr Opin Hematol. 2018 Jan;25(1):22-28. [PubMed: 28984748]

5.

Kirkwood CF, Smith LL, Rustagi PK, Schentag JJ. Neutropenia associated with beta-lactam antibiotics. Clin Pharm. 1983 Nov-Dec;2(6):569-78. [PubMed: 6653059]

6.

Burton IE, Moussa KM, Sanders PA. Agranulocytosis in rheumatoid arthritis associated with long-term flucloxacillin for staphylococcal osteomyelitis. Acta Haematol. 1995;94(4):196-8. [PubMed: 8610477]

7.

Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M. Descriptive epidemiology of agranulocytosis. Arch Intern Med. 1992 Jul;152(7):1475-80. [PubMed: 1627027]

8.

Apinantriyo B, Lekhakula A, Rujirojindakul P. Incidence, etiology and bone marrow characteristics of non-chemotherapy-induced agranulocytosis. Hematology. 2011 Jan;16(1):50-3. [PubMed: 21269568]

9.

Andrès E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol. 2011 Apr;4(2):143-51. [PubMed: 21495924]

10.

Andrès E, Maloisel F, Zimmer J. The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Br J Haematol. 2010 Jul;150(1):3-8. [PubMed: 20151980]

11.

Lally J, Malik S, Whiskey E, Taylor DM, Gaughran FP, Krivoy A, Flanagan RJ, Mijovic A, MacCabe JH. Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor/Granulocyte-Macrophage Colony-Stimulating Factor: A Systematic Review. J Clin Psychopharmacol. 2017 Aug;37(4):441-446. [PubMed: 28437295]

12.

Kubota Y, Toh Yoon EW. Severe Drug-Induced Agranulocytosis Successfully Treated with Recombinant Human Granulocyte Colony-Stimulating Factor. Case Rep Med. 2018;2018:8439791. [PMC free article: PMC5828046] [PubMed: 29560017]

13.

Arnold HM, McKinnon PS, Augustin KM, Hladnik LM, Casabar E, Reichley RM, Dubberke ER, Westervelt P, Ritchie DJ. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever. Pharmacotherapy. 2009 Aug;29(8):914-23. [PMC free article: PMC4256050] [PubMed: 19637944]

Disclosure: Yub Raj Sedhai declares no relevant financial relationships with ineligible companies.

Disclosure: Anish Lamichhane declares no relevant financial relationships with ineligible companies.

Disclosure: Vikas Gupta declares no relevant financial relationships with ineligible companies.